We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?
Read MoreHide Full Article
Key Takeaways
Amneal reported 4% revenue growth in first-quarter 2026, driven by broad business strength.
Amneal expects 2026 revenues of $3.05B-$3.15B, driven by new product launches.
AMRX's Affordable Medicines growth is expected to accelerate in 2026 with biosimilar launches.
Amneal Pharmaceuticals (AMRX - Free Report) has a diversified business model spanning generics, specialty drugs and government distribution.
Amneal operates through three segments — Affordable Medicines, Specialty and AvKARE. Affordable Medicines develops and markets retail generics, injectables and biosimilars across multiple dosage forms. Specialty focuses on branded drugs for neurological and endocrine disorders, while AvKARE distributes pharmaceuticals and other products to the U.S. government, retail and institutional markets.
Amneal offers an attractive growth story backed by its diversified portfolio, strong pipeline and an expanding presence in injectables and biosimilars. The company has been making steady progress with generics and new product launches, driving revenue and earnings growth.
Let’s discuss what factors make it a good investment choice.
Year to date, shares of Amneal have decreased 1.4% compared with the industry’s decline of 6.2%.
Image Source: Zacks Investment Research
AMRX’s Consistent Revenue and Profit Growth
Amneal has recorded strong revenues and profit growth for the past few years, driven by broad-based growth across its business. Its total revenues rose 4% year over year to $723 million in the first quarter of 2026. Revenues are expected to be in the range of $3.05 billion-$3.15 billion in 2026.
Affordable Medicines’ first-quarter revenues were $423 million, up 2% year over year. Segment growth was driven by the strong performance of the complex portfolio, including Women’s Health and ADHD medicines.
Affordable Medicines’ net revenues are expected to grow 7% to 8% in 2026, supported by new product launches. A key new product expected to be launched in 2026 is a biosimilar version of Novartis’ asthma drug, Xolair (presently under review).
Specialty segment’s first-quarter revenues of $133 million grew 23% year over year, with robust uptake of Crexont and steady Rytary and Unithroid growth.
AvKARE net revenues of $166 million declined 4% year over year in the first quarter as growth in the government channel was offset by a decline in the low-margin distribution channel.
Reflecting the strong overall business performance, the company is also expanding its EBITDA and cash flows. While adjusted EBITDA is expected to be in the range of $740-$770 in 2026, adjusted EPS is expected to be in the range of 95 cents to $1.05.
AMRX's Zacks Rank & Rising Estimates
Amneal currently has a Zacks Rank #2 (Buy). In the past 60 days, estimates for AMRX’s 2026 earnings per share have increased from 99 cents to $1.00. During the same period, earnings per share estimates for 2027 have moved up from $1.16 to $1.17.
Positive regulatory updates, an expanding pipeline and rising generics demand should help the stock gain further momentum in 2026.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $3.10 to $3.35, while estimates for 2027 have increased from $3.47 to $3.69. INDV’s shares have risen 4.6% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, 2026 loss per share estimates for Immunocore have narrowed from 97 cents to 16 cents, while estimates for 2027 have moved from a loss of 39 cents to earnings of 11 cents. IMCR stock has lost 16.9% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $1.50 to $2.97, while estimates for 2027 have increased from $2.91 to $4.81. LQDA’s shares have surged 76.8% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?
Key Takeaways
Amneal Pharmaceuticals (AMRX - Free Report) has a diversified business model spanning generics, specialty drugs and government distribution.
Amneal operates through three segments — Affordable Medicines, Specialty and AvKARE. Affordable Medicines develops and markets retail generics, injectables and biosimilars across multiple dosage forms. Specialty focuses on branded drugs for neurological and endocrine disorders, while AvKARE distributes pharmaceuticals and other products to the U.S. government, retail and institutional markets.
Amneal offers an attractive growth story backed by its diversified portfolio, strong pipeline and an expanding presence in injectables and biosimilars. The company has been making steady progress with generics and new product launches, driving revenue and earnings growth.
Let’s discuss what factors make it a good investment choice.
Year to date, shares of Amneal have decreased 1.4% compared with the industry’s decline of 6.2%.
Image Source: Zacks Investment Research
AMRX’s Consistent Revenue and Profit Growth
Amneal has recorded strong revenues and profit growth for the past few years, driven by broad-based growth across its business. Its total revenues rose 4% year over year to $723 million in the first quarter of 2026. Revenues are expected to be in the range of $3.05 billion-$3.15 billion in 2026.
Affordable Medicines’ first-quarter revenues were $423 million, up 2% year over year. Segment growth was driven by the strong performance of the complex portfolio, including Women’s Health and ADHD medicines.
Affordable Medicines’ net revenues are expected to grow 7% to 8% in 2026, supported by new product launches. A key new product expected to be launched in 2026 is a biosimilar version of Novartis’ asthma drug, Xolair (presently under review).
Specialty segment’s first-quarter revenues of $133 million grew 23% year over year, with robust uptake of Crexont and steady Rytary and Unithroid growth.
AvKARE net revenues of $166 million declined 4% year over year in the first quarter as growth in the government channel was offset by a decline in the low-margin distribution channel.
Reflecting the strong overall business performance, the company is also expanding its EBITDA and cash flows. While adjusted EBITDA is expected to be in the range of $740-$770 in 2026, adjusted EPS is expected to be in the range of 95 cents to $1.05.
AMRX's Zacks Rank & Rising Estimates
Amneal currently has a Zacks Rank #2 (Buy). In the past 60 days, estimates for AMRX’s 2026 earnings per share have increased from 99 cents to $1.00. During the same period, earnings per share estimates for 2027 have moved up from $1.16 to $1.17.
Positive regulatory updates, an expanding pipeline and rising generics demand should help the stock gain further momentum in 2026.
Other Stocks to Consider
Some other top-ranked stocks in the drug/biotech sector are Indivior Pharmaceuticals (INDV - Free Report) , Immunocore (IMCR - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $3.10 to $3.35, while estimates for 2027 have increased from $3.47 to $3.69. INDV’s shares have risen 4.6% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, 2026 loss per share estimates for Immunocore have narrowed from 97 cents to 16 cents, while estimates for 2027 have moved from a loss of 39 cents to earnings of 11 cents. IMCR stock has lost 16.9% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $1.50 to $2.97, while estimates for 2027 have increased from $2.91 to $4.81. LQDA’s shares have surged 76.8% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.